| Mune Gowda, MD | |
|
47601 Grand River Ave, Ste B129, Novi, MI 48374 | |
| (248) 305-8400 | |
| (348) 305-5880 |
| Full Name | Mune Gowda |
|---|---|
| Gender | Male |
| Speciality | Plastic And Reconstructive Surgery |
| Experience | 53 Years |
| Location | 47601 Grand River Ave, Novi, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023121910 | NPI | - | NPPES |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mune Gowda Md Pllc | 5496800427 | 2 |
News Archive
InterSystems Corporation, a global leader in software for connected care, today launched the next generation of its InterSystems HealthShare strategic informatics platform for interoperability and active analytics. Designed originally for public health information exchanges (HIEs) at regional, state and national levels, HealthShare has been extended and rearchitected to also deliver the advanced technologies needed by integrated delivery networks (IDNs).
The Center for Science in the Public Interest has sued the German drug company Bayer for falsely claiming that the selenium in Men's One A Day multivitamins might reduce the risk of prostate cancer. The lawsuit is filed in the Superior Court of California in San Francisco.
Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), today announced that the U.S. Food and Drug Administration approved LONSURF (trifluridine and tipiracil), formerly known as TAS-102, for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.
Endo Pharmaceuticals and Bioniche Life Sciences today presented Phase III trial results for the intravesical formulation of Mycobacterial cell wall-DNA complex (MCC), known as Urocidin, during a podium presentation at the 2011 American Urological Association annual meeting in Washington, D.C.
While studies have shown that diabetes education programs are crucial in helping individuals living with the disease self-manage their condition, a new study led by Ryerson researchers has found that less than half of primary-care physicians surveyed refer all of their patients with diabetes to these programs.
› Verified 1 days ago
| Entity Name | Mune Gowda Md Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033347646 PECOS PAC ID: 5496800427 Enrollment ID: O20090827000198 |
News Archive
InterSystems Corporation, a global leader in software for connected care, today launched the next generation of its InterSystems HealthShare strategic informatics platform for interoperability and active analytics. Designed originally for public health information exchanges (HIEs) at regional, state and national levels, HealthShare has been extended and rearchitected to also deliver the advanced technologies needed by integrated delivery networks (IDNs).
The Center for Science in the Public Interest has sued the German drug company Bayer for falsely claiming that the selenium in Men's One A Day multivitamins might reduce the risk of prostate cancer. The lawsuit is filed in the Superior Court of California in San Francisco.
Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), today announced that the U.S. Food and Drug Administration approved LONSURF (trifluridine and tipiracil), formerly known as TAS-102, for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.
Endo Pharmaceuticals and Bioniche Life Sciences today presented Phase III trial results for the intravesical formulation of Mycobacterial cell wall-DNA complex (MCC), known as Urocidin, during a podium presentation at the 2011 American Urological Association annual meeting in Washington, D.C.
While studies have shown that diabetes education programs are crucial in helping individuals living with the disease self-manage their condition, a new study led by Ryerson researchers has found that less than half of primary-care physicians surveyed refer all of their patients with diabetes to these programs.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mune Gowda, MD 47601 Grand River Ave, Ste B129, Novi, MI 48374 Ph: (248) 305-8400 | Mune Gowda, MD 47601 Grand River Ave, Ste B129, Novi, MI 48374 Ph: (248) 305-8400 |
News Archive
InterSystems Corporation, a global leader in software for connected care, today launched the next generation of its InterSystems HealthShare strategic informatics platform for interoperability and active analytics. Designed originally for public health information exchanges (HIEs) at regional, state and national levels, HealthShare has been extended and rearchitected to also deliver the advanced technologies needed by integrated delivery networks (IDNs).
The Center for Science in the Public Interest has sued the German drug company Bayer for falsely claiming that the selenium in Men's One A Day multivitamins might reduce the risk of prostate cancer. The lawsuit is filed in the Superior Court of California in San Francisco.
Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), today announced that the U.S. Food and Drug Administration approved LONSURF (trifluridine and tipiracil), formerly known as TAS-102, for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.
Endo Pharmaceuticals and Bioniche Life Sciences today presented Phase III trial results for the intravesical formulation of Mycobacterial cell wall-DNA complex (MCC), known as Urocidin, during a podium presentation at the 2011 American Urological Association annual meeting in Washington, D.C.
While studies have shown that diabetes education programs are crucial in helping individuals living with the disease self-manage their condition, a new study led by Ryerson researchers has found that less than half of primary-care physicians surveyed refer all of their patients with diabetes to these programs.
› Verified 1 days ago
Dr. Abdul Razzak Mahfouz, M.D. Surgery Medicare: Medicare Enrolled Practice Location: 24230 Karim Blbd, Suite# 125, Novi, MI 48375 Phone: 248-474-2700 Fax: 248-474-2721 | |
Dr. Jason J Rizqallah, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 47601 Grand River Ave # B136, Novi, MI 48374 Phone: 248-465-3940 Fax: 248-465-3941 | |
Dr. John A Gorski, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 25500 Meadowbrook Rd Ste 275, Novi, MI 48375 Phone: 248-516-3519 | |
Ms. Rasha Samer Kesto, PA-C Surgery Medicare: Not Enrolled in Medicare Practice Location: 47601 Grand River Ave, Novi, MI 48374 Phone: 248-465-4100 | |
Rebecca M Studinger, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 47601 Grand River Ave, Suite B129, Novi, MI 48374 Phone: 248-305-8400 | |
Ramachandra B Kolachalam, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 26850 Providence Parkway, #460, Novi, MI 48374 Phone: 248-662-4272 | |
Dr. Michael John Jacobs, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 26850 Providence Pkwy, Suite 504, Novi, MI 48374 Phone: 248-662-4333 Fax: 248-662-3022 |